Carvana Wedbush Upgrade Lifts Shares

Carvana Wedbush upgrade raised its 12-month price target to $400 and flagged unit growth and margin expansion, prompting renewed trader interest.

November 24, 2025·2 min read
View all news articles
Flat vector icon of a car merged with growth bands to represent Carvana Wedbush upgrade and unit growth forecasts.

KEY TAKEAWAYS

  • Wedbush upgraded Carvana to Outperform and raised its 12-month price target to $400.
  • The note forecast Q4 revenue of $5.2 billion and FY 2025 revenue of $19.9 billion.
  • Wedbush cited accelerating unit growth and margin expansion as the rationale.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Wedbush Securities upgraded Carvana (CVNA) to Outperform from Neutral on Nov. 24, 2025, citing stronger management execution, accelerating unit growth, and margin expansion. The firm raised its 12-month price target to $400 from $380, prompting shares to rise more than 7% following the note.

Wedbush Upgrade and Valuation

Wedbush viewed Carvana’s recent roughly 13% share price pullback as excessive and a buying opportunity. The firm values Carvana at about 22 times its 2027 earnings estimate, near the low end of the stock’s two-year trading range. The upgrade reflects confidence in the company’s ability to sustain growth and improve profitability.

Growth and Margin Outlook

Wedbush projects Carvana’s revenue will reach $5.2 billion in the fourth quarter of 2025, up 46.4% year-over-year, and $19.9 billion for the full year, a 45.6% increase. These gains are driven mainly by a 41.4% rise in used-unit sales, supported by sustained unit expansion and improved per-unit economics.

The firm expects Carvana to surpass CarMax in quarterly used-unit volumes by the fourth quarter of 2026, forecasting about 187,000 units compared with CarMax’s 170,000. Wedbush projects Carvana will scale to 3 million annual retail unit sales by 2033, implying a compound annual growth rate of at least 23% through that year.

Adjusted EBITDA margins are forecast to reach 12% by 2027, moving toward management’s longer-term target of 13.5% within five to ten years. Wedbush noted limited concern about credit performance despite Carvana’s expansion into lower-prime and subprime financing.

The firm’s valuation and profit assumptions underpin the higher price target and suggest potential for a re-rating if Carvana meets its volume and margin forecasts.

The near-term test of Wedbush’s outlook will come with Carvana’s fourth-quarter 2025 results and whether unit volumes and revenue align with projections. Progress toward the projected volume lead in late 2026 and the longer-term sales and margin goals will influence future valuation assessments.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Monday.com Earnings Beat, Guidance Disappoints

Monday.com Earnings Beat, Guidance Disappoints

monday.com earnings beat estimates but weaker guidance and front-loaded AI investments are likely to raise volatility and pressure trader positioning.

Yen Strengthens After Japan Election

Yen Strengthens After Japan Election

Yen strengthens after Japan election as Takaichi's LDP wins a record supermajority, raising odds of fiscal expansion and favoring Japanese equities.

Kroger Names Greg Foran CEO

Kroger Names Greg Foran CEO

Kroger Names Greg Foran CEO effective Feb. 9, 2026; the hire refocuses investor attention on operational fixes and store and digital execution.

EU Charges Meta Over WhatsApp AI Access

EU Charges Meta Over WhatsApp AI Access

EU Charges Meta over blocking rival AI on WhatsApp; the Commission intends interim measures that could force restored access and raise regulatory risk.

NatWest Evelyn Partners Acquisition Weighs on Shares

NatWest Evelyn Partners Acquisition Weighs on Shares

NatWest Evelyn Partners acquisition expands the bank's wealth franchise and prompted traders to weigh capital effects and a concurrent share buyback.

Hims Halts Semaglutide Pill After FDA Warning

Hims Halts Semaglutide Pill After FDA Warning

Hims Halts Semaglutide Pill as Hims & Hers stopped sales after an FDA enforcement warning on unapproved compounded GLP-1s, raising risk for DTC health stocks.